Letters
More on compulsory registration of clinical trials: GSK has created useful register
BMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7489.479-b (Published 24 February 2005) Cite this as: BMJ 2005;330:479
- Ronald Krall, senior vice president, Worldwide Development,
- Frank Rockhold (frank.w.rockhold@gsk.com), senior vice president, Biomedical Data Sciences
- GlaxoSmithKline, Upper Merion, PA 19087, USA
EDITOR—The editorial by Abbasi and letters in response illustrate the considerable interest in the registration of clinical trials.1 2 As a pharmaceutical company that has created a register to communicate the results of clinical trials of our marketed products, GlaxoSmithKline would like to bring to your attention the decisions we have taken to make our register worthwhile and meaningful to the medical profession and …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.